Key result
Rivaroxaban use in patients with nonvalvular atrial fibrillation was associated with low rates of thromboembolic events (1.3/100 patient-years) and major bleeding (1.9/100 patient-years).
Why the study?
Does rivaroxaban prevent stroke safely in patients with nonvalvular atrial fibrillation in real-world clinical practice?
Cohort (n=142)
No
Does rivaroxaban prevent stroke safely in patients with nonvalvular atrial fibrillation in real-world clinical practice?
Rivaroxaban demonstrated low rates of thromboembolic events and major bleeding in a real-world cohort of patients with nonvalvular atrial fibrillation.
Supports real-world rivaroxaban use in nonvalvular AF; hypothesis-generating and requires randomized confirmation.
AIM: To evaluate the clinical profile and effectiveness/safety of patients taking rivaroxaban in clinical practice. METHODS: Retrospective study that included patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke between January 2012 and December 2016 in a tertiary hospital in Spain. RESULTS: -VASc ≥2; 44.3% HAS-BLED ≥3) were included. Only two patients had a thromboembolic event (in both cases ischemic stroke) and three patients had major bleeding (rates of 1.3 and 1.9 events/100 patient years, respectively). CONCLUSION: Data regarding effectiveness and safety in our cohort were consistent with previous studies, showing that rivaroxaban can be effective and safely used in our setting.
No takes yet. Share an insight, caveat, or question.
Cerezo-Manchado et al. (2018) conducted a cohort in Nonvalvular Atrial Fibrillation (n=142). Rivaroxaban was evaluated on Thromboembolic event. Rivaroxaban use in patients with nonvalvular atrial fibrillation was associated with low rates of thromboembolic events (1.3/100 patient-years) and major bleeding (1.9/100 patient-years).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: